Anaphylatoxins: Their role in bacterial infection and inflammation

Immunologic Research

Volumn 37, Issue 3, 2007, Pages 161-175

  Haas, Pieter Jan ^a   Van Strijp, Jos ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anaphylatoxins; C3a; C4a; C5a; Complement; Immune evasion; Infection; Inflammation

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; MANNAN BINDING LECTIN;

ACYLATION; AMINO TERMINAL SEQUENCE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CARBOXY TERMINAL SEQUENCE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; DISEASE PREDISPOSITION; ENZYME DEGRADATION; ESTERIFICATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INNATE IMMUNITY; INTRACELLULAR KILLING; LEUKOCYTE ACTIVATION; LUNG INJURY; MEMBRANE DAMAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PUS; REVIEW; SEPSIS; SEQUENCE HOMOLOGY; SMOOTH MUSCLE CONTRACTILITY; STAPHYLOCOCCUS AUREUS;

ANAPHYLATOXINS; ANIMALS; BACTERIAL INFECTIONS; COMPLEMENT ACTIVATION; COMPLEMENT C3A; COMPLEMENT C4; COMPLEMENT C5A; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; RECEPTOR, ANAPHYLATOXIN C5A;

EID: 35348928319     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02697367     Document Type: Review

References (122)

1. HuberLang M, Sarma JV, Zetoune FS, et al: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006;12:682-687.
2. Barnum SR, Ames RS, Maycox PR, et al: Expression of the complement C3a and C5a receptors after permanent focal ischemia: an alternative interpretation. Glia 2002;38:169-173.
3. Dahinden CA, Bischoff SC, Brunner T, Krieger M, Takafuji, S, de Weck, A L: Regulation of mediator release by human basophils: importance of the sequence and time of addition in the combined action of different agonists. Int Arch Allergy Appl Immunol 1991;94:161-164.
4. Elsner J, Oppermann M, Czech W, Dobos G, Schöpf E, Norgauer, J, Kapp, A: C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 1994;24:518-522.
5. Epps DEV, Simpson, SJ, Johnson, R: Relationship of C5a receptor modulation to the functional responsiveness of human polymorphonuclear leukocytes to C5a. J Immunol 1993;150:246-252.
6. Hartmann K, Henz BM, Krüger-Krasagakes S, et al: C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997;89:2863-2870.
7. Nilsson G, Johnell M, Hammer CH, et al: C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996;157:1693-1698.
8. 2+ influx in neutrophils via a pertussis-toxin-sensitive G-protein. Eur J Biochem 1993;217:289-294.
9. Settmacher B, Bock D, Saad H, et al: Modulation of C3a activity: internalization of the human c3a receptor and its inhibition by C5a. J Immunol 1999;162:7409-7416.
10. http://www.ncbi.nlm.hih.gov/unigene/.
11. Beutler B: Innate immunity: an overview. Mol Immunol 2004;40:845-859.
12. Rooijakkers SHM, van Wamel WJB, Ruyken M, van Kessel, KPM, van Strijp, JAG: Anti-opsonic properties of staphylokinase. Microbes Infect 2005;7:476-484.
13. Bokisch VA, Mülller-Eberhard HJ, Cochrane CG: Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 1969;129:1109-1130.
14. Bokisch VA, Dierich MP, Müller-Eberhard HJ: Third component of complement (C3): structural properties in relation to functions. Proc Nail Acad Sci USA 1975;72:1989-1993.
15. Budzko DB, Bokisch VA, Müller-Eberhard HJ: A fragment of the third component of human complement with anaphylatoxin activity. Biochemistry 1971;10:1166-1172.
16. Gerard NR Gerard C: Complement in allergy and asthma. Curr Opin Immunol 2002;14:705-708.
17. Hawlisch H, Wills-Karp M, Karp CL, Kötfl, J: The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004;41:123-131.
18. Ames RS, Li Y, Sarau HM, et al: Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 1996;271:20231-20234.
19. Fischer WH, Hugli TE: Regulation of B cell functions by C3a and C3a(desarg): suppression of TNF-alpha, IL-6, and the polyclonal immune response. J Immunol 1997;159:4279-4286.
20. Francis K, Lewis BM, Akatsu H, et al: Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB J 2003;17:2266-2268.
21. Gasque P, Singhrao SK, Neal JW, et al: The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998;160:3543-3554.
22. Monsinjon T, Gasque P, Ischenko A, Fontaine M: C3a binds to the seven transmembrane anaphylatoxin receptor expressed by epithelial cells and triggers the production of IL-8. Febs Lett 2001;487:339-346.
23. Drouin SM, Corry DB, Kildsgaard J, Wetsel RA: Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2001;167:4141-4145.
24. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA: Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002;169:5926-5933.
25. Humbles AA, Lu B, Nilsson CA, et al: A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000;406:998-1001.
26. Cianflone K, Maslowska M, Sniderman AD: Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin Cell Dev Biol 1999;10:31-41.
27. Cianflone K, Xia Z, Chen LY: Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003;1609:127-43.
28. Murray I, Köhl J, Cianflone K: Acylation-stimulating protein (ASP): structure-function determinants of cell surface binding and triacylglycerol synthetic activity. Biochem J 1999;342 (Pt 1):41-48.
29. 'Xia Z, Stanhope KL, Digitale E, et al: Acylation-stimulating protein (asp)/complement C3a-des-arg deficiency results in increased energy expenditure in mice. J Biol Chem 2004;279:4051-4057.
30. Kalant D, MacLaren R, Cui W, et al: C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem 2005;280:23936-23944.
31. Gorski JP, Hugli TE, Müller-Eberhard, H J: C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci USA 1979;76:5299-5302.
32. Meuer S, Hugli TE, Andreatta RH, Hadding U, Bitter-Suermann D: Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). investigations on their ability to induce platelet secretion. Inflammation 1981;5:263-273.
33. - generation by C4a. Immunol Lett 1993;36:301-304.
34. Lienenklaus S, Ames RS, Tornetta MA, et al: Human anaphylatoxin C4a is a potent agonist of the guinea pig but not the human C3a receptor. J Immunol 1998;161:2089-2093.
35. Köhl J: Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001;38:175-187.
36. Guo RF, Ward, PA: Role of C5a in inflammatory responses. Annu Rev Immunol 2005;23:821-852.
37. Goldstein IM, Weissmann G: Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol 1974;113:1583-1588.
38. Marder SR, Chenoweth DE, Goldstein IM, Perez, HD: Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a, and C5a-des-arg. J Immunol 1985;134:3325-3331.
39. Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacob HS: Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes an in vitro model of immune vascular damage. J Clin Invest 1978;61:1161-1167.
40. Guo RE Huber-Lang M, Wang X, et al: Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest 2000;106:1271-1280.
41. Guo R, Riedemann NC, Laudes U, et al: Altered neutrophil trafficking during sepsis. J Immunol 2002;169:307-314.
42. Laudes IJ, Chu JC, Sikranth S, et al: Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002;160:1867-1875.
43. Laudes IJ, Chu JC, Huber-Lang M, et al: Expression and Nnction of C5a receptor in mouse microvascular endothelial cells. J Immunol 2002;169:5962-5970.
44. Perianayagam MC, Balakrishnan VS, King AJ, Pereira BJ, G, Jaber, BL: C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. Kidney Int 2002;61:456-463.
45. Perianayagam MC, Balakrishnan VS, Pereira BJG, Jaber BL: C5a delays apoptosis of human neutroptrils via an extracellular signal-regulated kinase and bad-mediated signalling pathway. Eur J Clin Invest 2004;34:50-56.
46. Riedemann NC, Guo R, Laudes IJ, et al: C5a receptor and thymocyte apoptosis in sepsis. FASEB J 2002;16:887-888.
47. Rennen HJ, Oyen WJ, Cain SA, Moak PN, Corstens FH, Boerman OC: Tc-99m-labeled C5a and C5a-desarg74 for infection imaging. Nucl Med Biol 2003;30:267-272.
48. Gerard NP, Gerard C: The chemotactic receptor for human C5a anaphylatoxin. Nature 1991;349:614-617.
49. Gerard C, Gerard NP: C5a anaphylatoxin and its seven transmembrane- segment receptor. Annu Rev Immunol 1994;12:775-808.
50. Bockaert J, Pin JP: Molecular tilkkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999;18:1723-1729.
51. Gao J, Choe H, Bota D, Wright PL, Gerard C, Gerard NP: Sulfation of tyrosine 174 in the human C3a receptor is essential for binding of C3a anaphylatoxin. J Biol Chem 2003;278:37902-37908.
52. Farzan M, Schnitzler CE, Vasilieva N, et al: Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a an aphylatoxin receptor. J Exp Med 2001;193:1059-1066.
53. Chert Z, Zhang X, Gonnella NC, Pellas TC, Boyar WC, Ni F: Residues 21-30 within the extracelhilar N-terminal région of the C5a receptor represent a binding domain for the C5a anaphylatoxin. J Biol Chem 1998;273:10411-10419.
54. Postma B, Kleibeuker W, Poppelier M J, et al: Residues 10-18 wittrin the C5a receptor N-terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus. J Biol Chem 2005;280:2020-2027.
55. Rollins TE, Siciliano S, Springer MS: Solubilization of the functional C5a receptor from human polymorphonuclear leukocytes. J Biol Chem 1988;263:520-526.
56. Rollins TE, Siciliano S, Kobayashi S, et al: Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex. Proc Natl Acad Sci USA 1991;88:971-975.
57. Siciliano SJ, Rollins TE, DeMartino J, et al: Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 1994;91:1214-1218.
58. Wetsel RA: Expression of the complement C5a anaphylatoxin receptor (C5ar) on non-myeloid cells. Immunol Lett 1995;44:183-187.
59. Wetsel RA: Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 1995;7:48-53.
60. Zwimer J, Fayyazi A, Gotze O: Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1999;36:877-884.
61. Gerard NP, Hodges MK, Drazen JM, Weller PE Gerard C: Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem 1989;264:1760-1766.
62. Kalant D, Cain SA, Maslowska M, et al: The chemoattractant receptor-like protein C5L2 binds the C3a-desarg77/acylation-stimulating protein. J Biol Chem 2003;278:11123-11129.
63. Cain SA, Monk PN: The orphan receptor c512 has high affinity binding sites for complement fragments C5a and C5a-des-arg(74). J Biol Chem 2002;277:7165-7169.
64. Gerard NP, Lu B, Liu E et al: An anti-inflammatory function for the complement anaphylatoxin C5-abinding protein, C5L2. J Biol Chem 2005;280:39677-39680.
65. Okinaga S, Slattery D, Humbles A, et al: C5L2, a nonsignaling C5a binding protein. Biochemistry 2003;42:9406-9415.
66. Kawamoto S, Yalcindag A, Laouini D, et al: The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen. J Clin Invest 2004;114:399-407.
67. Nakano Y, Morita S, Kawamoto A, Suda T, Chida K, Nakamura H: Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003;112:525-530.
68. Hasegawa K, Tamari M, Shao C, et al: Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004;115:295-301.
69. Fischer WH, Jagels MA, Hugli TE: Regulation of I1-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(des-arg). J Immunol 1999;162:453-459.
70. Schwartz LB, Kawahara MS, Hugli TE, Vik D, Fearon DT, Austen KF: Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol 1983;130:1891-1895.
71. Ali H, Panettieri RAJ: Anaphylatoxin C3a receptors in asthma. Respir Res 2005;6:19.
72. Mastellos D, Andronis C, Persidis A, Lambris JD: Novel biological networks modulated by complement. Clin Immunol 2005;115:225-235.
73. O'Barr SA, Caguioa J, Gruol D, et al: Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001;166:4154-4162.
74. Strey CW, Markiewski M, Mastellos D, et al: The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 2003;198:913-923.
75. Guo R, Riedemann NC Ward PA: Role of C5a-C5aR interaction in sepsis. Shock 2004;21:1-7.
76. Nakae H, Endo S, Inada K, Takakuwa T, Kasai T, Yoshida M: Serum complement levels and severity of sepsis. Res Commun Chem Pathol Pharmacol 1994;84:189-195.
77. Huber-Lang M, Sarma VJ, Lu KT, et al: Role of C5a in multiorgan failure during sepsis. J Immunol 2001;166:1193-1199.
78. Höpken U, Mohr M, Strüber A, et al: Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur J Immunol 1996;26:1103-1109.
79. Strieter RM, Kasahara K, Allen RM, et al: Cytokine-induced neutrophil-derived intefleukin-8. Am J Pathol 1992;141:397-407.
80. Monsinjon T, Gasque E Chan P, et al: Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003;17:1003-1014.
81. Pan ZK: Anaphylatoxins C5a and C3a induce nuclear factor kappa B activation in human peripheral blood monocytes. Biochim Biophys Acta 1998;1443:90-98.
82. Huber-Lang MS, Younkin EM, Sarma JV, et al: Complement-induced impairment of innate immunity during sepsis. J Immunol 2002;169:3223-3231.
83. Tulzo YL, Pangault C, Gacouin A, et al: Early circulating lymphocyte apoptosis in human septic shockis associated with poor outcome. Shock 2002;18:487-494.
84. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM: The role of the complement system in ischemia-reperfusion injury. Shock 2004;21:401-409.
85. Amsterdam EA, Statil GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC: Limitation of repeffusion injury by a monoclonal antibody to c5a during myocardial infarction in pigs. Am J Physiol 1995;268:H448-00H457.
86. Arumugam TV, Shiels IA, Woodruff TM, Reid RC, Fairlie DP, Taylor SM: Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res 2002;103:260-267.
87. Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM: A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 2003;63:134-142.
88. Arumugam TV, Woodruff TM, Stocks SZ, et al: Protective effect of a human C5a receptor antagonist against hepatic ischaemia-repeffusion injury in rats. J Hepatol 2004;40:934-941.
89. Heller T, Hennecke M, Baumann U, et al: Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol 1999;163:985-994.
90. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL: Myocardial ane infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-2267.
91. Wada K, Montalto, MC, Stahl GL: Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology 2001;120:126-133.
92. de Vries B, Köhl J, Leclercq WKG, et al: Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003;170:3883-3889.
93. Braun MC, Lahey E, Kelsall BL: Selective suppression of IL-12 production by chemoattractants. J Immunol 2000;164:3009-3017.
94. Wittmann M, Zwirner J, Larsson VA, et al: C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J Immunol 1999;162:6763-6769.
95. Haggar A, Hussain M, Lönnies H, et al: Extracellular adherence protein from Staphylococcus aureus enhances internalization into eukaryotic cells. Infect Immun 2003;71:2310-2317.
96. Karp CL, Grupe A, Schadt E, et al: Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000;1:221-226.
97. Karp CL, Wills-Karp M: Complement and IL-12: yin and yang. Microbes Infect 2001;3:109-119.
98. Abe M, Shibata K, Akatsu H, et al: Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 2001;167:4651-4660.
99. Köhl J, Baelder R, Lewkowich IP, et al: A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest 2006;116:783-796.
100. Shushakova N, Skokowa J, C5a anaphylatoxin is a major regulator of activating versus inhibitory fcgammars in immune complex-induced lung disease. J Clin Invest 2002;110:1823-1830.
101. Skokowa J, Ali SR, Felda O, et al: Macrophage s induce the inflammatory response in the pulmonary arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol 2005;174:3041-3050.
102. Kumar V, Ali SR, Konrad S, et al: Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 2006;116:512-520.
103. Rooijakkers S, van Strijp JA: Bacterial complement evasion. Mol Immunol 2007;44:23-32.
104. Rooijakkets SHM, Ruyken M, Roos A, etal: Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 2005;6:920-927.
105. Lee LYL, Liang X, Höök M, Brown EL: Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb). J Biol Chem 2004;279:50710- 50716.
106. Lee LYL, Höök M, Haviland D, et al: Inhibition of complement activation by a secreted Staphylococcus aureus protein. J Infect Dis 2004;190:571-579.
107. Al-Shangiti AM, Naylor CE, Nair SP, Briggs DC, Henderson B, Chain BM: Structural relationships and cellular tropism of staphylococcal superantigen-like proteins. Infect Immun 2004;72:4261-4270.
108. Al-Shangiti AM, Nair SE Chain BM: The interaction between staphylococcal superantigen-like proteins and human dendritic cells. Clin Exp Immunol 2005;140:461-469.
109. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD: The staphylococcal superantigen like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol 2005;174:2926-2933.
110. Wines BD, Willoughby N, Fraser JD, Hogarth PM: A competitive mechanism for staphylococcal toxin SSL7 inhibiting the leukocyte IgA receptor, Fc alpha RI, is revealed by SSL7 binding at the Calpha 2/Calpha 3 interface of IgA. J Biol Chem 2006;281:1389-13930.
111. Veldkamp KE, Van Kessel KP, Verhoef J, Van Strijp JA: Staphylococcal culture supernates stimulate human phagocytes. Inflammation 1997;21:541-551.
112. de Haas CJ, Veldkamp KE, Peschel A, et al: Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 2004;199:687-695.
113. Bronner S, Monteil H, Prévost G: Regulation of virulence determinants in Staphylococcus aureus: complexity and applications. Fems Microbiol Rev 2004;28:183-200.
114. Novick RP: Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 2003;48:1429-1449.
115. Rooijakkers SHM, Ruyken M, van Roon J, van Kessel KPM, van Strijp JAG, van Wamel WJB: Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus. Cell Microbiol 2006;8:1282-1293.
116. Postma B, Poppelier MJ, van Galen JC, et al: Chemotaxis inhibitory protein of staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J Immunol 2004;172:6994-7001.
117. Falk W, Harvath, L, Leonard FJ: Only the chemotactic subpopulation of human blood monocytes expresses receptors for the chemotactic peptide n-formylmethionylleucyl-phenylalanine. Infect Immun 1982;36:450-454.
118. Huey R, Hugli TE: Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN). J Immunol 1985;135:2063-2068.
119. Pike MC, Fischer DG, Koren HS, Snyderman R: Development of specific receptors for n-formylated chemotactic peptides in a human monocyte cell line stimulated with lymphokines. J Exp Med 1980;152:31-40.
120. Haas PJ, de Haas CJ, Kleibeuker W, et al: N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J Immunol 2004;173:5704-5711.
121. Haas P, de Haas CJC, Poppelier MJJC, et al: The structure of the C5a receptor-blocking domain of chemotaxis inhibitory protein of staphylococcus aureus is related to a group of immune evasive molecules. J Mol Biol 2005;353:859-872.
122. Rahimpour R, Mitchell G, Khandaker MH, et al: Bacterial superantigens induce down-modulation of CC chemokine responsiveness in human monocytes via an alternative chemokine ligand-independent mechanism. J Immunol 1999;162:2299-2307.